| Literature DB >> 30150589 |
Gergő Józsa1, Vince Szegeczki2, Andrea Pálfi3, Tamás Kiss4, Zsuzsanna Helyes5, Balázs Fülöp6, Csaba Cserháti7, Lajos Daróczi8, Andrea Tamás9, Róza Zákány10, Dóra Reglődi11, Tamás Juhász12.
Abstract
: Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with diverse developmental roles, including differentiation of skeletal elements. It is a positive regulatory factor of chondrogenesis and osteogenic differentiation in vitro, but little is known about its in vivo role in bone formation. In our experiments, diaphyses of long bones from hind limbs of PACAP gene-deficient mice showed changes in thickness and increased staining intensity. Our main goal was to perform a detailed morphological and molecular biological analysis of femurs from PACAP knockout (KO) and wild type (WT) mice. Transverse diameter and anterior cortical bone thickness of KO femurs showed significant alterations with disturbed Ca2+ accumulation and collagen type I expression. Higher expression and activity of alkaline phosphatase were also observed, accompanied by increased fragility PACAP KO femurs. Increased expression of the elements of bone morphogenic protein (BMP) and hedgehog signalling was also observed, and are possibly responsible for the compensation mechanism accounting for the slight morphological changes. In summary, our results show that lack of PACAP influences molecular and biomechanical properties of bone matrix, activating various signalling cascade changes in a compensatory fashion. The increased fragility of PACAP KO femur further supports the role of endogenous PACAP in in vivo bone formation.Entities:
Keywords: BMP; alkaline phosphatase activity; bone fragility; collagen expression; hedgehog; inorganic matrix
Mesh:
Substances:
Year: 2018 PMID: 30150589 PMCID: PMC6163297 DOI: 10.3390/ijms19092538
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Morphological analysis of hind limbs of wild type (WT) and pituitary adenylate cyclase activating polypeptide (PACAP) knockout (KO) mice. Whole limb alizarin red staining (A), optical density (OD) was determined in 1 cm distal part of the femur. Hematoxilin-eosin (HE) staining (B) to visualize the histological differences. Original magnification was 4×. Scale bar, 500 µm. CT analysis (C–G) of mouse femurs. Representative data of 5 independent experiments. Asterisks indicate significant (* p < 0.05) difference in thickness of cortical bone or in the diameter of diaphysis compared to the respective control.
Figure 2Investigation of inorganic matrix production of long bones. von Kossa (A) and alizarin red (B) staining of cryosectioned samples. Original magnification was 4×. Scale bar: 500 µm. Optical density (OD) was determined in microphotographs and normalised to wild type samples. mRNA (C) and protein (D) expression of alkaline phosphatase (ALP), osterix, osteocalcin and osteopontin of femurs. For reverse transcription followed by polymerase chain reaction (RT-PCR) and Western blot reactions, actin was used as control. Optical signal density was measured and results were normalised to the controls. For panels (C,D) numbers below signals represent integrated signal densities determined by ImageJ software. (E) ALP activity in compact bone. Asterisks indicate significant (* p < 0.05) alteration of ALP activity compared to the respective control. Representative data of 3 independent experiments.
Figure 3Collagen type I expression in femurs. (A) Collagen expression of cortical bone was visualized with picrosirius staining, and photomicrographs were made by polarization microscope. Original magnification was 20×. Scale bar: 200 µm. Numbers below the photos show the differences of concentric lamellas thickness. (B) Immunohistochemistry of collagen type I in cortical bones. Original magnification was 20×. Scale bar: 200 µm. mRNA (C) and protein (D) expression of collagen type I. For RT-PCR and Western blot reactions, actin was used as controls. Optical signal density was measured and results were normalised to the controls. For panels (C,D) numbers below signals represent integrated signal densities determined by ImageJ software. Asterisks indicate significant (* p <0.05) alteration of expression compared to the respective controls. Representative data of 3 independent experiments.
Figure 4PACAP signalisation in bones. (A) mRNA and (B) protein expression of pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1), vasoactive intestinal polypeptide receptor (VPAC)1, VPAC2,protein kinase A (PKA), cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), Runx2 in cortical bone. Actin was used as a control. Numbers below signals represent integrated signal densities determined by ImageJ software. Asterisks indicate significant (* p < 0.05) alteration of expression compared to the respective controls. Representative data of 3 independent experiments. (C) Immunohistochemistry of Runx2 in cortical bones. Original magnification was 60×. Scale bar: 5 µm. Representative data of 3 independent experiments.
Figure 5Signalling connections of PAC1 receptor. mRNA (A,D) and protein (B,E) expression of bone morphogenic protein (BMP)2, BMP4, BMP6, BMP7, BMPR1, Smad1, Indian Hedgehog (IHH), Sonic Hedgehog (SHH), Patched (PTCH)1 and Gli1 in cortical bone. For RT-PCR and Western blot reactions, actin was used as controls. Signals optical density was measured and results were normalised to the optical density of controls. For panels (A,D) and (B,E) numbers below signals represent integrated densities of signals determined by ImageJ software. (C) Smad1 immunohistochemistry in bones. Original magnification was 60×. Scale bar: 5 µm. (F) Three point bending tests of long bones. (a) Value of the loading force at crack (Fm), and (b) the value of the bending deformation at crack (Δlm) were demonstrated. Asterisks indicate significant (* p < 0.05) alteration of expression as compared to the respective control. Representative results of 3 independent experiments.
Figure 6Schematic drawing of the possible signalling pathways regulated by PACAP in bone formation. PAC1 receptor activation leads to the increase of intracellular cAMP, which activates PKA. Downstream targets of PKA can be CREB or Runx2 transcription factors which activations induce the expression of collagen type I, osterix, osteocalcin, ostepontin and ALP. BMP6 and BMP7 binding to BMPR1 triggers the activation of Smad cascade which can induce the expression of collagen type I, osterix, osteocalcin, ostepontin, ALP and IHH. The activation of BMP signalling is fine-tuned by the activation of PACAP signalling. Runx2 phosphorylation can occur via BMPR1 activation, showing a PACAP independent mechanism. IHH and SHH activate Gli1 transcription factor which is inhibited by PACAP signalling. This signalling pathway is also responsible for the activation of collagen type I and ALP expression. Increased ALP expression and activation elevates the Ca2+ phosphate production. PACAP signalling keeps a balance between BMP and hedgehog signalling activation via this regulates proper bone formation.
Nucleotide sequences, amplification sites, GenBank accession numbers, amplimer sizes and PCR reaction conditions for each primer pair are shown.
| Gene | Primer | Nucleotide Sequence (5′→3′) | GenBank ID | Annealing Temperature | Amplimer Size (bp) |
|---|---|---|---|---|---|
|
| sense | GAA GTC CGT GGG CAT CGT | NM013059 | 59 °C | 347 |
| antisense | CAG TGC GGT TCC AGA CAT AG | ||||
|
| sense | AAG CCA GGT GTC TCC AAG | NM017178.1 | 53 °C | 209 |
| antisense | AAG TCC ACA TAC AAA GGG TG | ||||
|
| sense | TAG TCC CAA GCA TCA CCC | NM012827.2 | 53 °C | 294 |
| antisense | TCG TAC TCG TCC AGA TAC AAC | ||||
|
| sense | CCC AGA TTC CTG AGG GTG A | NM013107.1 | 56 °C | 248 |
| antisense | CAT GTT GTG CTG CGG TGT | ||||
|
| sense | AGG GAG TCC GAC CTC TTC T | NM001191856.1 | 54 °C | 297 |
| antisense | GTT CTG GCT GCG TTG TTT | ||||
|
| sense | CCA TTG CTT TGC CAT TAT | NM009758.4 | 47 °C | 487 |
| antisense | TTT ACC AAC CTG CCG AAC | ||||
|
| sense | GGG CGA GTG CTG TGC TTT | NM007742.3 | 60 °C | 388 |
| antisense | GGG ACC CAT TGG ACC TGA A | ||||
|
| sense | AGA TTG CCA CAT TAG CCC | NM031017.1 | 52 °C | 441 |
| antisense | GCT GTA TTG CTC CTC CCT | ||||
|
| sense | GCC AAC CGT GAA AAG ATG A | NM007393.5 | 54 °C | 462 |
| antisense | CAA GAA GGA AGG CTG GAA AA | ||||
|
| sense | CCA CCC TAC CTC TGT CTA TTC G | NM010296.2 | 49 °C | 423 |
| antisense | CAC CCT TGT TCT GGT TTT ACC | ||||
|
| sense | CCA ACT ACA ATC CCG ACA TCA | NM053384.1 | 58 °C | 477 |
| antisense | GTC TTC ATC CCA GCC TTC C | ||||
|
| sense | GCC TAC TTA CCC GTC TGA CTT T | NM001037632.1 | 56 °C | 131 |
| antisense | GCC CAC TAT TGC CAA CTG C | ||||
|
| sense | TAA GGT GGT GAA TAG ACT CCG | NM013414.1 | 56 °C | 143 |
| antisense | CCT GGA AGC CAA TGT GGT | ||||
|
| sense | CTA CGC CCT TTA CTA CCC AG | NM016989.2 | 49 °C | 247 |
| antisense | GTA TTT CTT GAC AGC CAT TTG T | ||||
|
| sense | GCA AAG GCT ACA ACA AGG C | NM008854 | 53 °C | 280 |
| antisense | ATG GCA ATC CAG TCA ATC G | ||||
|
| sense | GCT GAA GCC TGA CCC ATC T | X51834 | 59 °C | 494 |
| antisense | TCC CGT TGC TGT CCT GAT | ||||
|
| sense | GGA ACT TAT CAC GGA GAC AG | NM053566.1 | 56 °C | 368 |
| antisense | AAC CTT GAC ATC CAC CAT T | ||||
|
| sense | GGA CGA GGC AAG AGT TTC A | NM001278483.1 | 55 °C | 249 |
| antisense | TGG TGC AGA GTT CAG GGA G | ||||
|
| sense | TCG TGC TAC GCA GTC ATC G | NM017221.1 | 56 °C | 156 |
| antisense | CCT CGC TTC CGC TAC AGA | ||||
|
| sense | AGC ACC TAC CCT CAC TCC C | NM013130.2 | 56 °C | 306 |
| antisense | GAA ACC ATC CAC CAA CAC G | ||||
|
| sense | GTT CTA TGG CAC GGT CAA | NM001097523 | 52 °C | 216 |
| antisense | AGC AAT GTT CGG GTT CTC | ||||
|
| sense | TCG GAA CTA CAT CCA TCT | NM001014970 | 48 °C | 177 |
| antisense | TTT GCC ATA ACA CCA TAC |
Tables of antibodies used in the experiments.
| Antibody | Host Animal | Dilution | Distributor |
|---|---|---|---|
| Anti-PAC1 | rabbit, polyclonal, | 1:600 | Sigma-Aldrich, St. Louis, MO, USA |
| Anti-VPAC1 | rabbit, polyclonal, | 1:800 | Alomone Labs., Jerusalem, Israel |
| Anti-VPAC2 | rabbit, polyclonal, | 1:600 | Abcam, Camridge, UK |
| Anti-Coll. I. | mouse, monoclonal, | 1:1000 | Sigma-Aldrich, St. Louis, MO, USA |
| Anti-CREB | rabbit, polyclonal, | 1:800 | Millipore, Billerica, MA, USA |
| Anti-P-CREB | rabbit, polyclonal, | 1:800 | Millipore, Billerica, MA, USA |
| Anti-Osterix | rabbit, polyclonal, | 1:200 | SantaCruz Biotechnology Inc., Santa Cruz, CA, USA |
| Anti-Osteocalcin | rabbit, polyclonal, | 1:600 | Abcam, Camridge, UK |
| Anti-Osteopontin | rabbit, polyclonal, | 1:500 | Abcam, Camridge, UK |
| Anti-ALP | rabbit, polyclonal, | 1:500 | Abcam, Camridge, UK |
| Anti-SHH | rabbit, polyclonal, | 1:600 | Cell Signaling, Danvers, MA, USA |
| Anti-IHH | rabbit, polyclonal, | 1:600 | Millipore, Billerica, MA, USA |
| Anti-PKA | rabbit, polyclonal, | 1:800 | Cell Signaling, Danvers, MA, USA |
| Anti-Runx2 | rabbit, polyclonal, | 1:500 | Cell Signaling, Danvers, MA, USA |
| Anti-Gli1 | rabbit, polyclonal, | 1:600 | Cell Signaling, Danvers, MA, USA |
| Anti-BMP2 | mouse, monoclonal, | 1:500 | Abcam, Camridge, UK |
| Anti-BMP4 | rabbit, polyclonal, | 1:600 | Cell Signaling, Danvers, MA, USA |
| Anti-BMP6 | rabbit, polyclonal, | 1:200 | SantaCruz Biotechnology Inc., Santa Cruz, CA, USA |
| Anti-BMP7 | rabbit, polyclonal, | 1:600 | Abcam, Camridge, UK |
| Anti-BMPR1 | mouse, monoclonal, | 1:600 | Abcam, Camridge, UK |
| Anti-Smad1 | rabbit, polyclonal, | 1:600 | Cell Signaling, Danvers, MA, USA |
| Anti-PTCH1 | rabbit, polyclonal, | 1:800 | Cell Signaling, Danvers, MA, USA |
| Anti-Actin | mouse, monoclonal, | 1:10,000 | Sigma-Aldrich, St. Louis, MO, USA |